Inventor
STOTT COLIN
GB17 patents
⚠️ This page may combine multiple inventors who share the name “STOTT COLIN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
GW RES LTD
7 patentsUS11684598B2Jun 27, 2023
Use of cannabinoids in the treatment of epilepsy
GW RES LTD17 citations94
US11147783B2Oct 19, 2021
Use of cannabinoids in the treatment of epilepsy
GW RES LTD30 citations94
US11793770B2Oct 24, 2023
7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy
GW RES LTD18 citations93
US11147776B2Oct 19, 2021
7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy
GW RES LTD33 citations93
US10098867B2Oct 16, 2018
Use of phytocannabinoids in the treatment of ovarian carcinoma
GW RES LTD39 citations91
US11065227B2Jul 20, 2021
Use of cannabinoids in the treatment of multiple myeloma
GW RES LTD38 citations90
US10226433B2Mar 12, 2019
Use of cannabinoids in the treatment of degenerative skeletal muscle diseases
GW RES LTD15 citations82
GW PHARMA LTD
6 patentsUS9962341B2May 8, 2018
Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
GW PHARMA LTD27 citations93
US9675579B2Jun 13, 2017
Tetrahydrocannabivarin for use in the treatment of nausea and vomiting
GW PHARMA LTD55 citations93
US10758514B2Sep 1, 2020
Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour
GW PHARMA LTD22 citations92
US9675654B2Jun 13, 2017
Phytocannabinoids in the treatment of cancer
GW PHARMA LTD17 citations89
US11413266B2Aug 16, 2022
Use of cannabinoids in the treatment of inflammatory skin diseases
GW PHARMA LTD15 citations80
US10039724B2Aug 7, 2018
7-hydroxy cannabidiol (7-OH-CBD) for use in the treatment of non-alcoholic fatty liver disease (NAFLD)
GW PHARMA LTD15 citations78